Skip to main content
OpenTrials
Completed

NCT Number: NCT02695849

A Study of Prevalence of EGFR Mutations in Participants With NSCLC

This is a non-interventional, local, multicenter, cross-sectional study to determine the prevalence of epidermal growth factor receptor (EGFR) mutations in participants diagnosed with non-squamous non-small cell lung cancer (NSCLC).

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Amman, Jordan

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Informed consent form signature
  • Jordanian male and female participants greater than or equal to (>=) 18 years of age
  • Histologically confirmed NSCLC
  • Not participating in a study that involves an investigational agent within 30 days prior to enrollment

Exclusion criteria

  • Other primary malignancy
  • Fine needle aspiration samples

Treatment and study plan

Primary outcomes

  1. Percentage of Participants with EGFR mutations

    Time frame: Day 1

Secondary outcomes

  1. Percentage of Participants with types of EGFR mutations

    Time frame: Day 1

Sponsors and collaborators

Lead sponsor

Hoffmann-La Roche

Industry

Registry information

Official study title

An Epidemiology Study of the Prevalence of Epidermal Growth Factor Receptor (EGFR) Mutations in Patients Diagnosed With Non-squamous Non-small Cell Lung Cancer (NSCLC)

Important dates

Study start
2012
Primary completion
2015
Study completion
2015
First posted
Mar 1, 2016
Registry last updated
Jul 4, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.